Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
3 hedge funds and large institutions have $6.79M invested in Hepion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
53% more capital invested
Capital invested by funds: $4.44M → $6.79M (+$2.35M)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Teachers Advisors
New York
|
+$559K |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
+$559K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.37M |
| 2 |
Goldman Sachs
New York
|
-$14K |
| 3 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$6K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$1K |
HEPA Hedge Fund Activity: Q2 2016 in Review
3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2016, worth a combined $6.79M — up 53% from $4.44M a quarter earlier.
Fund positioning in HEPA was balanced in Q2 2016: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Teachers Advisors, opening a new position worth an estimated $559K. The largest seller was Anson Funds Management, exiting entirely with an estimated $1.37M sold.
- 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $6.79M of Hepion Pharmaceuticals stock for Q2 2016, up 53% quarter-over-quarter.
- 1 fund opened new Hepion Pharmaceuticals positions in Q2 2016 and 1 closed out, a net change of 0 holders.
- The largest Hepion Pharmaceuticals buyer in Q2 2016 was Teachers Advisors, an estimated $559K added.
- The largest Hepion Pharmaceuticals seller in Q2 2016 was Anson Funds Management, an estimated $1.37M sold.
Based on aggregated 13F filings for Q2 2016.